Assessment of risk for developing coronary heart disease in asymptomatic individuals

Journal of Cardiopulmonary Rehabilitation and Prevention

Volumn 29, Issue 4, 2009, Pages 207-219

  Kappagoda, C Tissa ^a,b   Amsterdam, E A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

Carotid ultrasound; Coronary calcium score; Emerging risk factors; Framingham risk score

Indexed keywords

CELL ADHESION MOLECULE; CREATININE; FIBRINOGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; VERY LOW DENSITY LIPOPROTEIN;

ANKLE BRACHIAL INDEX; ARTERY DISEASE; ATHEROSCLEROSIS; BLOOD PRESSURE; CAROTID ARTERY BRUIT; CORONARY CALCIUM SCORE; DIABETES MELLITUS; ELECTROCARDIOGRAM; EXERCISE TEST; FAMILY HISTORY; FRAMINGHAM RISK SCORE; FUNCTIONAL STATUS; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL EXAMINATION; METABOLIC SYNDROME X; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SMOKING; ST SEGMENT DEPRESSION; TREADMILL EXERCISE; ULTRASOUND;

ATHEROSCLEROSIS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DIAGNOSIS, DIFFERENTIAL; ELECTROCARDIOGRAPHY; HUMANS; INCIDENCE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 68749104869     PISSN: 19327501     EISSN: 1932751X     Source Type: Journal    
DOI: 10.1097/HCR.0b013e3181af6be5     Document Type: Review

References (58)

1. Canto JG, Iskandrian AE. Major risk factors for cardiovascular disease: debunking the "only 50%" myth. JAMA. 2003;290:947-949.
2. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891-897. (Pubitemid 37430460)
3. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904. (Pubitemid 37430461)
4. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952. (Pubitemid 39208455)
5. Wilson PW. Cardiovascular risk assessment - where are we going? Prev Cardiol. 2008;11:183-184.
6. Abbot RD, McGee D. The probability of developing certain cardiovascular diseases in eight years at specified values of some characteristics: The Framingham Study. In: Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Springfield, VA: National Technical Information Service; 1987:section 37. National Technical Information Service No. BP 87-221644/A5.
7. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335:136. (Pubitemid 47172233)
8. Woodward M, Brindle P, Tinstall-Pedoe H. Adding social deprivation and family history to the cardiovascular risk assessment: the assign score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93:172-176. (Pubitemid 46180289)
9. Zhang XF, Attia J, D'Este C, Yu XH, Wu XG. A risk score predicted coronary heart disease and stroke in a Chinese cohort. J Clin Epidemiol. 2005;58:951-958. (Pubitemid 41115780)
10. Jackson R. Updated New Zealand cardiovascular risk-benefit prediction guide. BMJ. 2000;320:709-710. (Pubitemid 30179401)
11. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003. (Pubitemid 36712275)
12. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847. (Pubitemid 28213628)
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
14. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183. (Pubitemid 23044857)
15. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720-732.
16. Greenland P, Lloyd-Jones D. Defining a national approach to screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol. 2008;52:330-332. (Pubitemid 352005812)
17. Cohn JN, Duprez DN. Time to foster a rational approach to preventing cardiovascular morbid events. J Am Coll Cardiol. 2008;52:327-329.
18. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.
19. Bruce RA, McDonough JR. Stress testing for screening for cardiovascular diseases. Bull N Y Acad Med. 1969;45:1288-1305.
20. Froelicher VF, Thomas M, Pillow C, Lancaster MC. An epidemiologic study of asymptomatic men screened with exercise testing for coronary artery disease. Am J Cardiol. 1974;34:770-776.
21. Doyle JT, Kinch SH. The prognosis of an abnormal electrocardiographic stress test. Circulation. 1970;41:545-553.
22. Okin PM, Anderson KM, Levy D, Kligfield P. Heart rate adjustment of exercise induced ST segment depression. Improved risk stratification in the Framingham Offspring Study. Circulation. 1991;83:866-874.
23. Balady GJ, Larson MG, Ramachandran S, et al. Usefulness of exercise testing in the prediction of coronary disease risk among asymptomatic persons as a function of the Framingham risk score. Circulation. 2004;110:1920-1925.
24. Pilote L, Pashkow F, Thomas JD, et al. Clinical yield and cost of exercise treadmill testing to screen for coronary artery disease in asymptomatic adults. Am J Cardiol. 1998;81:219-224. (Pubitemid 28057207)
25. Mora S, Redberg R, Sharrett AR, Blumenthal RS. Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores. Circulation. 2005;112:1566-1572. (Pubitemid 41324517)
26. Buddoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification. J Am Coll Cardiol. 2007;49:1860-1870.
27. Vliegenthart R, Oudkerk M, Hofman A, et al. Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation. 2005;112:572-577. (Pubitemid 41060798)
28. Lakosi SG, Greenland P, Wong N, et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score. Arch Intern Med. 2007;167:2437-2442.
29. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2007;49:378-402.
30. Michos ED, Vasamreddy C, Becker DM, et al. Women with a low Framingham score and a family history of premature coronary artery disease have a high prevalence of subclinical coronary artery atherosclerosis. Am Heart J. 2005;150:1276-1281. (Pubitemid 41773534)
31. Taylor AJ, Bindeman J, Feuerstein I, Cao F, Brazaitis M, O'Malley PG. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors. J Am Coll Cardiol. 2005;46:807-814.
32. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210-215. (Pubitemid 38082815)
33. Belcaro G, Nicolaides AN, Ramaswami G, et al. Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE Study). Atherosclerosis. 2001;156:379-387. (Pubitemid 32522919)
34. Chambless LE, Folsom AR, Sharrett AR, et al. Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. J Clin Epidemiol. 2003;56:880-890. (Pubitemid 37162663)
35. Pickett CA, Jackson JL, Hemann BA, Atwood JE. Carotid bruit as a prognostic indicator of cardiovascular death and myocardial infarction: meta analysis. Lancet. 2008;371:1587-1594.
36. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ. Mortality over ten years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
37. Newman AB, Siscovick DS, Manoli TA, Polak J, Fried LP, Borhani O. Ankle-arm index as a marker for atherosclerosis in the cardiovascular health study. Circulation. 1993;88:837-845. (Pubitemid 23263998)
38. Leng GC, Fowkes FGR, Lee AJ, Dunbar J, Houseley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ. 1996;313:1440-1443. (Pubitemid 26408032)
39. Ankle Brachial Collaboration. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197-208.
40. Lloyd-Jones DM, Byung-Ho Nam B-H, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291:2204-2211. (Pubitemid 38608169)
41. Murabito JM, Pencina MJ, Nam BH, et al. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2005;294:3117-3123.
42. Nasir K, Budoff MJ, Wong ND, et al. Family history of premature coronary heart disease and coronary artery calcification: Multi Ethnic Study of Atherosclerosis (MESA). Circulation. 2007;116:619-626. (Pubitemid 47356346)
43. Blumenthal R, Becker DM, Yanek LR, et al. Detecting occult coronary disease in a high risk asymptomatic population. Circulation. 2003;107:702-707. (Pubitemid 36222597)
44. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639. (Pubitemid 44969122)
45. Marcovina SM, Hegele RA, Koschinsky ML. Lipoprotein(a) and coronary heart disease risk. Curr Cardiol Rep. 1999;1:105-111.
46. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008;101(suppl 1):s23-s33.
47. Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis. 2002;163:377-384. (Pubitemid 34615830)
48. Cantin B, Després JP, Lamarche B, et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (the Quebec Cardiovascular Study). Am J Cardiol. 2002;89:662-666. (Pubitemid 34230560)
49. Marcovina SM, Koschinsky ML. A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin Vasc Med. 2002;2:335-344.
50. Sudhir K. Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction. Vasc Health Risk Manag. 2006;2:153-156. (Pubitemid 43853429)
51. Packard CJ, O'Reilly DSJ, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predicted of coronary heart disease. N Engl J Med. 2000;343:1148-1155. (Pubitemid 30781985)
52. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers. Arch Intern Med. 2006;166:1368-1373.
53. Mosca L, Mochari H, Christian AH, et al. National study of women's awareness, preventive action, and barriers to cardiovascular health. Circulation. 2006;113:525-534. (Pubitemid 43754353)
54. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for assessment of global cardiovascular risk in women. JAMA. 2007;297:611-619.
55. Ridker PM, Cook NR, Lee I-Min, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
56. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52-58.
57. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
58. US Preventive Services Taskforce. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med. 2002;136:157-160. (Pubitemid 34073942)